Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a biotechnology company with a market capitalization of $1.07 billion, recently executed a series of stock ...

So should Enliven Therapeutics (NASDAQ:ELVN) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each ...

根据提交给美国证券交易委员会的Form 4文件显示，市值10.7亿美元的生物科技公司Enliven Therapeutics, Inc. (NASDAQ: ELVN )首席财务官Benjamin Hohl近期进行了一系列股票交易。根据InvestingPro数据，该公司整体财务健康状况评级为"良好"。2月5日，Hohl以平均价格22.52美元出售了1,000股普通股，总售价为22,524美元。

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...